◈ Nootpedia
Compact view
Research pass: thorough AAS · Oil injectable SKIP-FOR-NOW HIGH

Testosterone Cypionate

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Testosterone cypionate is pharmacologically near-identical to enanthate (slightly longer ester, same molecule, same effects); the SKIP-AT-20 logic for any exogenous testosterone applies here too — endogenous T is at lifetime peak, HPG suppression risk is real, fertility impact possible, and zero documented benefit in eugonadal 20yo males. Verdict flips only with documented hypogonadism (total T <300 ng/dL × 2 morning draws + symptoms) — and even then enclomiphene is preferred first-line in young men. Revisit at 35-40+ if natural decline crosses symptomatic threshold.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-AT-

    endogenous T at lifetime peak; HPG suppression risk + fertility + mood/lipid hits + zero documented benefit at this age unless pathology present. No cognitive benefit established for eugonadal young men. Verdict re-evaluates after June 2026 panel; only flips with documented hypogonadism (T <300 ng/dL × 2 + symptoms), and even then enclomiphene preferred first-line.

  • 30-50, executive maintenance
    CONDITIONAL

    only with documented low T + symptoms. Enclomiphene preferred first-line for those wanting fertility preservation. Cypionate appropriate for those who've completed family planning and accept lifelong commitment.

  • 50+, mild cognitive decline / sarcopenia
    STRONG

    (if symptomatic low T) — TRAVERSE evidence supports CV safety at TRT doses in hypogonadal men. Cypionate is gold standard at this profile. Target T 450-600 ng/dL trough.

  • Dylan35-40+ natural decline (Dylan's revisit window)
    REVISIT-AT-AGE

    Natural T begins declining ~1%/yr after age 30; clinical hypogonadism prevalence rises substantially by 40s-50s. If Dylan crosses symptomatic threshold (low libido, fatigue, mood, body comp despite optimized lifestyle) AND total T <300-400 ng/dL on multiple morning draws — cypionate becomes a STRONG candidate after enclomiphene trial.

  • Anxiety-prone
    C

    — supra doses can amplify anxiety/irritability; TRT-dose effect variable.

  • High athletic load, tested status
    CATEGORICALLY EXCLUDED

    WADA-banned (S1 exogenous androgen). Detection window: ester lingers 3-6 months post-injection; metabolites detectable longer.

  • DylanHigh athletic load, untested status (Dylan's MMA scenario)
    OPTIONAL

    with caveats. Some MMA promotions have testing (USADA — UFC, recently transitioned out; PFL, Bellator with varying programs); state athletic commissions have testing. Untested regional/local promotions are gray zone. AAS use carries health risk, fertility risk, dependence — and Dylan's brain-priority profile + age 20 still makes this SKIP regardless of testing status.

  • Sleep-disordered
    C

    — can worsen OSA via Hct + soft tissue.

  • Recovery-focused (post-injury, post-illness)
    S

    low-dose has B-tier evidence in catabolic illness recovery (HIV wasting, severe burns) but not relevant to standard gym/sport injuries.

  • Strength/anabolic-focused
    E

    for goal but skip at 20 — endogenous ceiling not yet hit; train + eat + sleep first. Revisit at 30+ if natural ceiling reached.

  • Gender-affirming care (transmasculine)
    STRONG

    cypionate is standard masculinizing HRT (50-100 mg/wk IM/SubQ titrated to male reference range). Outside scope of Dylan's profile but flagged for completeness.

  • Anti-aging clinic context (40+ healthy "low-normal")
    CONTROVERSIAL

    Endocrine Society sets threshold at 300 ng/dL; many anti-aging clinics treat at 400-500 with symptoms. Genuine debate; risk-benefit thinner than for clinical hypogonadism. Cypionate is the modal molecule used in this gray-zone practice.

▸ Subjective experience (deep)
  • Onset (TRT 100-200 mg/wk): Subtle. Energy, morning erections, sleep, mood improve over 2-6 weeks. Body comp shifts over 3-6 months.
  • Onset (supraphysiologic 400-600 mg/wk): Noticeable libido + drive surge within 1-2 weeks, training aggression, faster recovery, water retention, mood lift bordering on hypomania for some.
  • Peak: Plateau by week 4-6. Sustained anabolic effect for cycle duration.
  • Taper / post-cycle: Without PCT, crash 2-3 weeks post-last-injection (one ester half-life clearance). Profound fatigue, libido collapse, depressed mood, fat regain, strength loss for 1-6 months. PCT (SERM-based) speeds recovery but doesn't guarantee it.
  • Characteristic signature vs other esters: Indistinguishable from enanthate in subjective experience. Slightly less peak-trough roller coaster than propionate (which requires EOD injections); flatter than sustanon (which has multi-ester sawtooth PK in some users).
▸ Tolerance + cycling deep dive
  • Tolerance buildup: None to AR effects directly — receptor remains responsive indefinitely. "Tolerance" people describe is to the subjective lift (the "feel" plateaus while body comp continues responding). E2 management often resolves perceived tolerance.
  • Recommended cycle (if pursued — NOT for Dylan):
    • TRT context: continuous, no cycling, indefinite (lifelong commitment).
    • Performance context: 10-16 week blast → PCT → minimum 12-16 week off-cycle for HPG recovery. "Blast and cruise" (continuous low-dose between blasts) sacrifices natural recovery permanently.
  • Reset protocol if needed (PCT):
    • Stop T, wait for ester clearance (~3-4 weeks for cypionate — same as enanthate practically).
    • SERM stack: clomiphene 50 mg/d × 4 wk → 25 mg/d × 4 wk; or tamoxifen 20 mg/d × 4-6 wk; or enclomiphene 12.5-25 mg/d (preferred — fewer side effects than racemic clomiphene).
    • hCG sometimes added during cycle to maintain testicular volume (250-500 IU 2-3x/week) — does NOT prevent intratesticular suppression long-term but speeds PCT recovery.
    • Recovery panel: 4 weeks post-PCT; full natural recovery often takes 3-12 months, sometimes never in younger users with longer cycles.
▸ Stacking deep dive

Synergistic with

  • N/A for Dylan — compound is SKIP at this profile. For TRT context only:
  • Anastrozole / aromatase inhibitor: Manages E2 at supraphysiologic doses. Rarely needed at TRT doses; over-suppression of E2 produces joint pain, low libido, lipid issues — modern TRT trends away from routine AI use.
  • hCG (250-500 IU 2x/wk): Maintains testicular volume + intratesticular T for fertility preservation in younger TRT patients; can be combined with cyp lifelong.
  • Enclomiphene: Ironically used DURING cyp in some "stacked" TRT protocols to preserve LH/FSH signal — relatively novel approach.
  • Finasteride (caveat): For hair preservation — blocks 5α-reductase; controversial trade-off (post-finasteride syndrome risk; possibly attenuates anabolic effect in muscle).

Avoid stacking with

  • Methyltestosterone or other oral 17αAA: Hepatotoxic; redundant + dangerous. See methyltestosterone.md — strictly dominated.
  • Trenbolone / Deca / other AAS in young men: Each adds specific harms (Tren = neuro/CV/sleep nightmare; Deca = prolactin, "deca dick", much longer suppression).
  • High-dose stimulants (modafinil + caffeine + ECA stacks): Compounds CV strain (HR + BP + Hct).
  • Alcohol (heavy): Compounds lipid + BP + hepatic load.

Neutral / safe co-administration

  • Fish oil / EPA (lipid panel mitigation)
  • Telmisartan or other ARB (BP management if hypertension develops)
  • Standard V4 stack (NAC, magnesium, creatine, etc.) — no known interaction
  • Modafinil at standard dose — pharmacokinetically independent
▸ Drug interactions deep dive
  • CYP3A4: Testosterone is a substrate; strong inhibitors (ketoconazole, ritonavir) raise levels modestly. CYP3A4 inducers (rifampin, carbamazepine) modestly reduce.
  • Anticoagulants (warfarin): T potentiates warfarin → INR monitoring required, dose adjustment likely.
  • Insulin / oral diabetics: T improves insulin sensitivity → may require diabetic dose reduction.
  • Corticosteroids: Additive Na/water retention; additive HPA effects.
  • Oxyphenbutazone: Increased oxyphenbutazone levels (per FDA label).
  • Propranolol: Possible altered metabolism.
  • GnRH agonists/antagonists: Antagonistic — exogenous T blunts utility.
▸ Pharmacogenomics
  • AR CAG repeat polymorphism: Shorter CAG repeats (<22) → more sensitive AR → potentially more anabolic + side effect response at given dose. Longer (>24) → less sensitive. Dylan's 23andMe (June 2026) can hint via raw data analysis.
  • CYP19A1 (aromatase) variants: Affect E2 conversion rate — some men aromatize aggressively at low doses, others resist; relevant to AI need.
  • SRD5A2 (5α-reductase): Variants affect DHT conversion — relevant to hair, prostate, skin side effect risk.
  • HSD17B (17β-hydroxysteroid dehydrogenase): Variants affect ester cleavage and T/DHT interconversion — minor effect on PK.
  • For Dylan: 23andMe pending June 2026. Genetic profile would inform sensitivity but cannot override the SKIP-AT-20 verdict — the issue isn't genetic susceptibility, it's that exogenous T suppresses an HPG axis at lifetime peak with no demonstrated upside.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (TRT clinic / telehealth) Hone Health, Marek Health, Defy Medical, Maximus, Gameday Men's Health $80-200/mo all-in (incl. labs + visits) High Requires bloodwork showing T <300 ng/dL or below clinic threshold + symptoms; many telehealth clinics have looser thresholds (some treat at 400-500 ng/dL with symptoms). NOT recommended in absence of pathology.
US Rx (compounding pharmacy via PCP/endocrinologist) Empower, Olympia, Hallandale $30-80/mo for 10mL vial High Cheapest legitimate route. Requires diagnosis. 200 mg/mL standard concentration.
US Rx commercial (Depo-Testosterone) Pfizer (brand), generics by Hikma, West-Ward, Perrigo $150-400/mo via insurance, $300-600 cash High FDA-approved 1957. 100 mg/mL or 200 mg/mL in cottonseed oil. Insurance typically covers for diagnosed hypogonadism.
US Rx commercial (subQ auto-injector) Xyosted (testosterone enanthate, not cyp — but functionally equivalent) $200-600/mo High Brand markup; covered by insurance.
Indian generic Rx Sun, Cipla, Aristo $5-15/vial when sourced via India pharma Medium Available in India OTC-ish; importing to US illegal at scale.
Gray-market UGL "research lab" / overseas sources $40-80 per 10 mL vial Variable Quality roulette; sterility + dose accuracy not guaranteed; mail interception risk; legal exposure (Schedule III felony). NOT recommended for Dylan.
▸ Biomarkers to track (deep)
  • Baseline (before any T discussion — Dylan's June 2026 panel):
    • Total testosterone (AM, fasted, 2 separate draws if low or borderline)
    • Free testosterone (calculated or measured by equilibrium dialysis)
    • SHBG
    • LH, FSH (rules out primary vs secondary hypogonadism)
    • Estradiol (sensitive assay — LC-MS/MS preferred over standard immunoassay)
    • Prolactin
    • Hematocrit, hemoglobin
    • Lipid panel (HDL, LDL, ApoB, Lp(a))
    • PSA (baseline even at 20 if T discussed; mandatory >40)
    • LFTs (AST, ALT, GGT)
    • HbA1c, fasting insulin, glucose
    • Thyroid: TSH, free T4, free T3
    • Comprehensive metabolic panel
  • During use (if ever pursued):
    • 6 weeks post-start: T trough (just before next injection), E2, Hct, lipid
    • 3 months: full panel
    • 6 months: full panel + PSA
    • Annually: full panel + DRE if indicated
    • Every 6 months: hematocrit (donate blood / phlebotomy if >54%)
  • Post-cycle (if cycled, e.g., supraphysiologic blast):
    • 4 weeks post-last-injection: T, LH, FSH, E2
    • 12 weeks post: confirm HPG recovery
    • Sperm analysis if fertility goals (cryopreserve sperm pre-cycle as insurance)
▸ Controversies / open debates Live debate
  • Cypionate vs enanthate "preference": Largely tribal — US prescribers cyp-default, EU enanthate-default. Mechanistically interchangeable; clinical outcomes identical at equivalent mg/wk. The strongest argument for cypionate in US is supply chain reliability and PCP familiarity.
  • "Bioidentical" framing: True at the molecule level (T is T) but misleading — exogenous T suppresses endogenous regardless of ester or molecule shape. The "natural" branding of TRT marketing oversells safety.
  • TRT at "low normal" T (300-450 ng/dL): Endocrine Society sets threshold at 300 ng/dL; many telehealth clinics treat at 400-500 with symptoms. Genuine controversy — some men have low SHBG and adequate free T despite low total. Free T or bioavailable T may be better criterion.
  • Cardiovascular risk: Pre-TRAVERSE (2010-2015) concern was elevated MACE (FDA black box added in 2014); TRAVERSE (2023) reassured for hypogonadal CV-risk men at TRT doses. Does NOT clear supraphysiologic doses or healthy young users.
  • Fertility recovery: Some men recover fully post-PCT; others remain subfertile/infertile. Risk factors for non-recovery: longer cycles, higher doses, age >35, baseline low FSH. Younger users at 20 are NOT protected — multiple case reports of permanent oligospermia after a single heavy cycle. Sperm cryopreservation pre-cycle is harm reduction.
  • SubQ vs IM: SubQ produces flatter PK with equivalent efficacy and reduced Hct rise. IM remains standard but SubQ is increasingly preferred in modern TRT practice. No reason to choose IM over SubQ for new TRT initiations except patient preference.
  • MMA / combat sport context: USADA exit from UFC (2023-2024) reshuffled detection landscape; CSAD (Combat Sports Anti-Doping) and state commissions now primary testing bodies. Detection windows for cypionate metabolites: months. Real risk for any tested fight; gray zone in untested regional promotions. Health argument against use stands independent of testing.
  • Brain development at 20: PFC matures into mid-20s; supraphysiologic androgens during this window may affect impulsivity-related neural development (animal data + theoretical concern; limited direct human evidence). Soft concern but worth flagging for Dylan-archetype users.
  • Mental health: Aggression literature contested — meta-analyses show modest increase in irritability/aggression at supra doses, large individual variance. Combat sport context plus supraphysiologic androgen plus age 20 is a combination worth flagging conservatively.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-AT-20 (HIGH confidence). Rationale: testosterone cypionate is mechanistically near-identical to enanthate (same molecule, ~8d vs ~7d half-life ester); the SKIP-AT-20 logic for any exogenous testosterone applies. Endogenous T at lifetime peak in healthy 20yo, HPG suppression with documented fertility/mood/lipid risks, no demonstrated benefit in eugonadal young men. Re-evaluate post June 2026 bloodwork; only flips to "conditional TRT" with documented hypogonadism (total T <300 ng/dL × 2 morning draws + symptoms). Even then, enclomiphene preferred first-line for fertility preservation. Revisit window: age 35-40+ if natural T crosses symptomatic threshold despite optimized lifestyle.
▸ Open questions / gaps Open
  • Dylan's June 2026 baseline T, LH, FSH, SHBG — until in hand, this verdict is partially blind. If unexpectedly low T + low LH/FSH at 20 (secondary hypogonadism pattern), enclomiphene is strongly indicated before any cypionate consideration.
  • AR CAG repeat from 23andMe (raw data analysis post-June 2026) — would inform sensitivity if T ever discussed.
  • Subconcussive impact effect on HPG axis: emerging literature suggests pituitary microtrauma in contact athletes may produce secondary hypogonadism. Worth checking if June panel shows unexpected low T + low LH/FSH pattern in Dylan.
  • Family history of hypogonadism, fertility issues, testicular pathology — TBD per profile.
  • MMA promotion testing landscape circa 2026 — varies by promotion and state commission; would inform tested-vs-untested decision matrix if Dylan ever crossed into competitive AAS-relevant decisions.
▸ Sources (full, with our context)
  • Depo-Testosterone (testosterone cypionate) — FDA label — current FDA prescribing information; PK, dosing, contraindications, drug interactions.
  • Bhasin S et al. "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men." NEJM 1996;335:1-7. — Foundational dose-response (used enanthate; cypionate equivalent at equimolar dose).
  • Lincoff AM et al. "Cardiovascular safety of testosterone-replacement therapy." NEJM 2023;389:107-117 (TRAVERSE). — CV non-inferiority in hypogonadal men with elevated CV risk; cypionate the dominant ester used.
  • Mulhall JP et al. "Evaluation and management of testosterone deficiency: AUA guideline." J Urol 2018, updated 2024. — Diagnostic + treatment thresholds.
  • Bhasin S et al. "Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline." JCEM 2018;103:1715-1744.
  • Spratt DI et al. "Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection." JCEM 2017;102:2647-2655. — SubQ PK + clinical data.
  • Kovac JR et al. "Patient satisfaction with testosterone replacement therapies: SubQ vs IM." Urology 2018. — Real-world preference data.
  • Rasmussen JJ et al. "Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation." PLoS One 2016. — Long-term HPG suppression risk.
  • Coward RM et al. "Anabolic steroid induced hypogonadism in young men." J Urol 2013;190:2200-2205. — Permanent infertility risk in young AAS users.
  • Zitzmann M. "Pharmacogenetics of testosterone replacement therapy." Pharmacogenomics 2009. — AR CAG repeat polymorphism effects.
  • WADA Prohibited List 2026 — S1 exogenous androgen classification (banned in and out of competition).
  • Testosterone cypionate — DrugBank DB13943 — pharmacology, mechanism, indications, interactions.
  • Testosterone cypionate — PubChem CID 5995 — chemical structure, CAS 58-20-8.
Back to compact view